Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gentian Diagnostics ASA ( (DE:6FK) ) has issued an update.
Gentian Diagnostics ASA reported an insider share purchase by its Chief Technology Officer, Frank Frantzen, who acquired 3,115 shares at NOK 40.00 per share. Following the transaction, Frantzen holds a total of 23,115 shares and 50,000 options in the company.
The move underscores continuing insider confidence in Gentian’s prospects and triggers standard disclosure obligations under the Norwegian Securities Trading Act, the EU Market Abuse Regulation and Euronext Oslo rules. The company has submitted the required PDMR notification, reinforcing transparency for investors and other market participants.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a Norwegian diagnostics company focused on developing and supplying in vitro diagnostic tests. The company operates in the medical technology and laboratory diagnostics industry, with its shares listed on the Oslo market and subject to Norwegian and EU securities regulations.
Average Trading Volume: 19,953
Current Market Cap: NOK610.7M
Learn more about 6FK stock on TipRanks’ Stock Analysis page.